Department of Anesthesia, Stanford University School of Medicine, Stanford, California 94305, USA.
Pharmacogenet Genomics. 2013 Feb;23(2):78-83. doi: 10.1097/FPC.0b013e32835cb2c7.
We investigated whether human pharmacogenetic factors could be characterized using chimeric NOG mice expressing a thymidine kinase transgene (TK-NOG) with 'humanized' livers.
The rate of human-specific metabolism of two drugs was measured in chimeric mice reconstituted with human hepatocytes with different CYP2C19 and CYP2C9 genotypes.
The rate of generation of human-predominant drug metabolites for S-mephenytoin and diclofenac in the chimeric mice was correlated with the CYP2C19 (n=9 donors, P=0.0005) or CYP2C9 (n=7 donors, P=0.0394) genotype, respectively, of the transplanted human hepatocytes.
This study suggests that TK-NOG mice reconstituted with hepatocytes obtained from a relatively small number (3-10 per genotype) of human donors may be a promising model to identify human pharmacogenetic factors affecting the metabolism of clinically important drugs. For certain compounds, this innovative model system enables pharmacogenetic analyses to be efficiently performed in vivo within a human context and with control of all confounding environmental variables.
我们研究了是否可以使用表达胸苷激酶转基因(TK-NOG)的嵌合 NOG 小鼠来表征人类药物遗传学因素,这些小鼠具有“人源化”的肝脏。
用具有不同 CYP2C19 和 CYP2C9 基因型的人肝细胞重建嵌合小鼠,测量两种药物的两种人特异性代谢物的生成率。
嵌合小鼠中 S-美芬妥因和双氯芬酸的人优势药物代谢物的生成率与移植的人肝细胞的 CYP2C19(n=9 供体,P=0.0005)或 CYP2C9(n=7 供体,P=0.0394)基因型分别相关。
这项研究表明,用来自相对较少数量(每种基因型 3-10 个)人供体的肝细胞重建的 TK-NOG 小鼠可能是一种很有前途的模型,可以识别影响临床重要药物代谢的人类药物遗传学因素。对于某些化合物,这种创新的模型系统可以在体内以人类背景和控制所有混杂的环境变量的方式进行有效的药物遗传学分析。